2020, Número S2
<< Anterior Siguiente >>
Rev Mex Traspl 2020; 9 (S2)
Tratamiento de COVID-19 en receptores de trasplante renal
Villca-Gonzales R, Morales-Buenrostro LE
Idioma: Español
Referencias bibliográficas: 97
Paginas: 173-187
Archivo PDF: 385.63 Kb.
RESUMEN
El presente artículo hace una revisión del tratamiento de COVID-19 en el contexto del paciente con trasplante renal. Por un lado, se discute el manejo de la inmunosupresión y por el otro lado, las terapias que hasta el momento se han publicado en relación al manejo de esta nueva enfermedad viral y sus complicaciones. La evidencia hasta el momento es limitada a series de casos o cohortes sin adecuados controles, con pocos ensayos clínicos, pero existen muchos estudios clínicos en curso, mejor diseñados, que podrían cambiar las conductas actuales de tratamiento en el corto plazo.
REFERENCIAS (EN ESTE ARTÍCULO)
Cravedi P, Suraj SM, Azzi Y, Haverly M, Farouk S, Perez-Saez MJ et al. COVID-19 and kidney transplantation: results from the TANGO International Transplant Consortium. Am J Transplant. 2020.
Akalin E, Azzi Y, Bartash R, Seethamraju H, Parides M, Hemmige V et al. Covid-19 and Kidney Transplantation. N Engl J Med. 2020; 382: 2475-2477.
Zaza G, Benedetti C, Fribourg M, Maggiore U, Azzi J, Riella LV et al. SARS-CoV-2 pandemic and the need for transplant-oriented trials. Transpl Int. 2020; 33: 966-968.
Morales-Buenrostro LE. Terapia de inducción con anticuerpos monoclonales y policlonales: basiliximab, timoglobulina y alemtuzumab. In: Alberú JL. Trasplantomecum renal. 2ª ed. Barcelona, España: Publicaciones Permanyer; 2011. pp. 69-75.
Ekberg H, Bernasconi C, Tedesco-Silva H, Vitko S, Hugo C, Demirbas A et al. Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation. Am J Transplant. 2009; 9: 1876-1885.
Florman S, Becker T, Bresnahan B, Chevaile-Ramos A, Carvalho D, Grannas G et al. Efficacy and safety outcomes of extended criteria donor kidneys by subtype: subgroup analysis of BENEFIT-EXT at 7 years after transplant. Am J Transplant. 2017; 17: 180-190.
Zaltzman JS. Is there a role for mTOR inhibitors in renal transplantation? Transplantation. 2017; 101: 228-229.
Hu Q, Zhong Z, Xiong Y, Ye S, Wang Y, Ye Q. Management of immunosuppression in kidney transplant recipients with COVID-19 pneumonia: a summary of 41 confirmed cases reported worldwide. Transpl Infect Dis. 2020: e13425.
Gandolfini I, Delsante M, Fiaccadori E, Zaza G, Manenti L, Degli Antoni A et al. COVID-19 in kidney transplant recipients. Am J Transplant. 2020; 20: 1941-1943.
Maggiore U, Abramowicz D, Crespo M, Mariat C, Mjoen G, Peruzzi L et al. How should I manage immunosuppression in a kidney transplant patient with COVID-19? An ERA-EDTA DESCARTES expert opinion. Nephrol Dial Transplant. 2020; 35: 899-904.
Vistoli F, Furian L, Maggiore U, Caldara R, Cantaluppi V, Ferraresso M et al. COVID-19 and kidney transplantation: an Italian Survey and Consensus. J Nephrol. 2020; 33: 667-680.
Mirjalili M, Shafiekhani M, Vazin A. Coronavirus disease 2019 (COVID-19) and transplantation: pharmacotherapeutic management of immunosuppression regimen. Ther Clin Risk Manag. 2020; 16: 617-629.
Pereira MR, Mohan S, Cohen DJ, Husain SA, Dube GK, Ratner LE et al. COVID-19 in solid organ transplant recipients: Initial report from the US epicenter. Am J Transplant. 2020; 20: 1800-1808.
Willicombe M, Thomas D, McAdoo S. COVID-19 and calcineurin inhibitors: should they get left out in the storm? J Am Soc Nephrol. 2020; 31: 1145-1146.
Marx D, Moulin B, Fafi-Kremer S, Benotmane I, Gautier G, Perrin P et al. First case of COVID-19 in a kidney transplant recipient treated with belatacept. Am J Transplant. 2020; 20: 1944-1946.
Ahmad SH, Smith R, Camilleri B. Belatacept, kidney transplantation and COVID-19: Successful management of the first reported case within the United Kingdom. Clin Transplant. 2020: e14026.
Nguyen LS, Vautier M, Allenbach Y, Zahr N, Benveniste O, Funck-Brentano C et al. Sirolimus and mTOR inhibitors: a review of side effects and specific management in solid organ transplantation. Drug Saf. 2019; 42: 813-825.
Johnson KM, Belfer JJ, Peterson GR, Boelkins MR, Dumkow LE. Managing COVID-19 in renal transplant recipients: a review of recent literature and case supporting corticosteroid-sparing immunosuppression. Pharmacotherapy. 2020; 40: 517-524.
Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020; 395: 473-475.
Cao W, Liu X, Bai T, Fan H, Hong K, Song H et al. High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019. Open Forum Infect Dis. 2020; 7: ofaa102.
Xie Y, Cao S, Dong H, Li Q, Chen E, Zhang W et al. Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19. J Infect. 2020; 81 (2): 318-356.
Choi J, Aubert O, Vo A, Loupy A, Haas M, Puliyanda D et al. Assessment of tocilizumab (anti-interleukin-6 receptor monoclonal) as a potential treatment for chronic antibody-mediated rejection and transplant glomerulopathy in hla-sensitized renal allograft recipients. Am J Transplant. 2017; 17: 2381-2389.
Fontana F, Alfano G, Mori G, Amurri A, Tei L, Ballestri M et al. COVID-19 pneumonia in a kidney transplant recipient successfully treated with tocilizumab and hydroxychloroquine. Am J Transplant. 2020; 20: 1902-1906.
Hammami MB, Garibaldi B, Shah P, Liu G, Jain T, Chen PH et al. Clinical course of COVID-19 in a liver transplant recipient on hemodialysis and response to tocilizumab therapy: a case report. Am J Transplant. 2020; 20 (8): 2254-2259.
Wong A. COVID-19 and toxicity from potential treatments: panacea or poison. Emerg Med Australas. 2020; 32 (4): 697-699.
Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020; 56 (1): 105949.
Mahevas M, Tran VT, Roumier M, Chabrol A, Paule R, Guillaud C et al. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. BMJ. 2020; 369: m1844.
Borba MGS, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, Brito M et al. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. JAMA Netw Open. 2020; 3: e208857.
Al-Tawfiq JAA-H, A.H. Memish, Z.A. Remdesivir as a possible therapeutic option for the COVID-19. Travel Med Infect Dis. 2020; 34: 101615.
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30: 269-271.
Cao YC, Deng QX, Dai SX. Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: an evaluation of the evidence. Travel Med Infect Dis. 2020; 35: 101647.
Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A et al. Compassionate use of remdesivir for patients with severe COVID-19. N Engl J Med. 2020; 382 (24): 2327-2336.
Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK et al. COVID-19 in critically ill patients in the Seattle region - case series. N Engl J Med. 2020; 382 (21): 2012-2022.
Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020; 395 (10236): 1569-1578.
Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci. 2017; 93: 449-463.
Sissoko D, Laouenan C, Folkesson E, M’Lebing AB, Beavogui AH, Baize S et al. Experimental treatment with favipiravir for Ebola virus disease (the JIKI trial): a historically controlled, single-arm proof-of-concept trial in Guinea. PLoS Med. 2016; 13: e1001967.
Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering (Beijing). 2020.
Chen C, Huang J, Cheng Z, Wu J, Chen S, Zhang Y et al. Favipiravir versus arbidol for COVID-19: a randomized clinical trial. medRxiv. 2020.
Irie K, Nakagawa A, Fujita H, Tamura R, Eto M, Ikesue H et al. Pharmacokinetics of favipiravir in critically ill patients with COVID-19. Clin Transl Sci. 2020:10.1111/cts.12827.
Cvetkovic RS, Goa KL. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs 2003; 63: 769-802.
Chu CM, Cheng VC, Hung IF, Wong MM, Chan KH, Chan KS et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004, 59: 252-256.
Chan KS, Lai ST, Chu CM, Tsui E, Tam CY, Wong MM et al. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med J 2003; 9: 399-406.
Chinese Clinical Guidance for COVID-19 Pneumonia Diagnosis and Treatment (7th edition). [Accessed March 22 2020] Available in: http://kjfy.meetingchina.org/msite/news/show/cn/3337.html..
Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G et al. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N Engl J Med. 2020; 382: 1787-1799.
Schoergenhofer C, Jilma B, Stimpfl T, Karolyi M, Zoufaly A. Pharmacokinetics of lopinavir and ritonavir in patients hospitalized with coronavirus disease 2019 (COVID-19). Ann Intern Med. 2020; M20-1550.
Hung IF, Lung KC, Tso EY, Liu R, Chung TW, Chu MY et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020; 395: 1695-1704.
Arabi YM, Shalhoub S, Mandourah Y, Al-Hameed F, Al-Omari A, Al Qasim E et al. Ribavirin and interferon therapy for critically ill patients with middle east respiratory syndrome: a multicenter observational study. Clin Infect Dis. 2020; 70: 1837-1844.
Song Y, Zhang M, Yin L, Wang K, Zhou Y, Zhou M et al. COVID-19 treatment: close to a cure? A rapid review of pharmacotherapies for the novel coronavirus (SARS-CoV-2). Int J Antimicrob Agents. 2020; 106080.
Zhang J, Zhou L, Yang Y, Peng W, Wang W, Chen X. Therapeutic and triage strategies for 2019 novel coronavirus disease in fever clinics. Lancet Respir Med. 2020, 8: e11-e12.
Lian N, Xie H, Lin S, Huang J, Zhao J, Lin Q. Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study. Clin Microbiol Infect. 2020; 26: 917-921.
Wang BX, Fish EN. Global virus outbreaks: Interferons as 1st responders. Semin Immunol. 2019; 43: 101300.
Zhou Q, Chen V, Shannon CP, Wei XS, Xiang X, Wang X et al. Interferon-alpha2b treatment for COVID-19. Front Immunol. 2020; 11: 1061.
Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020, 130: 2620-2629.
Panel. C-TG. Coronavirus disease 2019 (COVID-19) treatment guidelines. National Institutes of Health. [Accessed July 17th, 2020] Available at: https://http://www.covid19treatmentguidelines.nih.gov/.
Crisafulli S, Isgro V, La Corte L, Atzeni F, Trifiro G. Potential role of anti-interleukin (IL)-6 drugs in the treatment of COVID-19: rationale, clinical evidence and risks. BioDrugs. 2020;
Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents. 2020; 55: 105954.
Sciascia S, Apra F, Baffa A, Baldovino S, Boaro D, Boero R et al. Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19. Clin Exp Rheumatol. 2020; 38: 529-532.
Xu X, Han M, Li T, Sun W, Wang D, Fu B et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA. 2020; 117: 10970-10975.
Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: a single center experience. J Med Virol. 2020; 92: 814-818.
Toniati P, Piva S, Cattalini M, Garrafa E, Regola F, Castelli F et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia, Italy. Autoimmun Rev. 2020; 19: 102568.
Benucci M, Giannasi G, Cecchini P, Gobbi FL, Damiani A, Grossi V et al. COVID-19 pneumonia treated with sarilumab: a clinical series of eight patients. J Med Virol. 2020; 10.1002/jmv.26062.
Della-Torre E, Campochiaro C, Cavalli G, De Luca G, Napolitano A, La Marca S et al. Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. Ann Rheum Dis. 2020; annrheumdis-2020-218122.
Palanques-Pastor T, Lopez-Briz E, Poveda Andres JL. Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19. Eur J Hosp Pharm. 2020; ejhpharm-2020-002322.
Cavalli G, De Luca G, Campochiaro C, Della-Torre E, Ripa M, Canetti D et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020; 2: e325-e331.
Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med. 2006; 3: e343.
Arabi YM, Mandourah Y, Al-Hameed F, Sindi AA, Almekhlafi GA, Hussein MA et al. Corticosteroid therapy for critically ill patients with middle east respiratory syndrome. Am J Respir Crit Care Med. 2018; 197: 757-767.
Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Lim WS. Corticosteroids as adjunctive therapy in the treatment of influenza. Cochrane Database Syst Rev. 2016; 3: CD010406.
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395: 507-513.
Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020; 180 (7): 1-11.
Yang Z, Liu J, Zhou Y, Zhao X, Zhao Q, Liu J. The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis. J Infect. 2020; 81: e13-e20.
Group RC, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL et al. Dexamethasone in hospitalized patients with COVID-19-preliminary report. N Engl J Med. 2020.
Perez EE, Orange JS, Bonilla F, Chinen J, Chinn IK, Dorsey M et al. Update on the use of immunoglobulin in human disease: A review of evidence. J Allergy Clin Immunol. 2017; 139: S1-S46.
Sakoulas G, Geriak M, Kullar R, Greenwood K, Habib M, Vyas A et al. Intravenous immunoglobulin (IVIG) significantly reduces respiratory morbidity in COVID-19 pneumonia: a prospective randomized trial. medRxiv 2020.07.20.20157891; doi: https://doi.org/10.1101/2020.07.20.20157891 2020.
Shao Z, Feng Y, Zhong L, Xie Q, Lei M, Liu Z et al. Clinical efficacy of intravenous immunoglobulin therapy in critical patients with COVID-19: A multicenter retrospective cohort study. medRxiv. 2020; Preprint. Available at: https://http://www.medrxiv.org/content/10.1101/2020.04.11.20061739v2. 2020.
Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med. 2006; 145: 599-609.
Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw FM, Lim WS et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015; 211: 80-90.
Cheng Y, Wong R, Soo YO, Wong WS, Lee CK, Ng MH et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005; 24: 44-46.
Wang X, Guo X, Xin Q, Pan Y, Hu Y, Li J et al. Neutralizing antibodies responses to SARS-CoV-2 in COVID-19 inpatients and convalescent patients. Clin Infect Dis. 2020; ciaa721.
Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA. 2020; e2010044.
Liu ST, Lin HM, Baine I, Wajnberg A, Gumprecht JP, Rahman F et al. Convalescent plasma treatment of severe COVID-19: a matched control study. medRxiv. 2020; Preprint. Available at: https://http://www.medrxiv.org/content/10.1101/2020.05.20.20102236v1. 2020.
Salazar E, Perez KK, Ashraf M, Chen J, Castillo B, Christensen PA et al. Treatment of coronavirus disease 2019 (COVID-19) patients with convalescent plasma. Am J Pathol. 2020; 190: 1680-1690.
Olivares-Gazca JC, Priesca-Marin JM, Ojeda-Laguna M, Garces-Eisele J, Soto-Olvera S, Palacios-Alonso A et al. Infusion of convalescent plasma is associated with clinical improvement in critically ill patients with COVID-19: a pilot study. Rev Invest Clin. 2020; 72: 159-164.
Ye M, Fu D, Ren Y, Wang F, Wang D, Zhang F et al. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. J Med Virol. J Med Virol. 2020; 10.1002/jmv.25882.
Zeng QL, Yu ZJ, Gou JJ, Li GM, Ma SH, Zhang GF et al. Effect of convalescent plasma therapy on viral shedding and survival in patients with coronavirus disease 2019. J Infect Dis. 2020; 222: 38-43.
Joyner MJ, Wright RS, Fairweather D, Senefeld JW, Bruno KA, Klassen SA et al. Early safety indicators of COVID-19 convalescent plasma in 5,000 patients. J Clin Invest. 2020;
Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin-angiotensin-aldosterone system blockers and the risk of COVID-19. N Engl J Med. 2020; .
Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB et al. Renin-angiotensin-aldosterone system inhibitors and risk of COVID-19. N Engl J Med. 2020; 382 (25): 2441-2448.
Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular disease, drug therapy, and mortality in COVID-19. N Engl J Med. 2020; 382 (25): e102.
Flacco ME, Acuti Martellucci C, Bravi F, Parruti G, Cappadona R, Mascitelli A et al. Treatment with ACE inhibitors or ARBs and risk of severe/lethal COVID-19: a meta-analysis. Heart. 2020;
Grover A, Oberoi M. A systematic review and meta-analysis to evaluate the clinical outcomes in COVID-19 patients on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Eur Heart J Cardiovasc Pharmacother. 2020; pvaa064.
Pirola CJ, Sookoian S. Estimation of renin-angiotensin-aldosterone-system (RAAS)-inhibitor effect on COVID-19 outcome: a meta-analysis. J Infect. 2020; 81 (2): 276-281.
Verdecchia PC, Spanevello C, Angeli A, F. The pivotal link between ACE2 deficiency and SARSCoV-2 infection. Eur J Intern Med. 2020; 76: 14-20.
Brogi SC, V. Off-target ACE2 ligands: possible therapeutic option for CoVid-19? Br J Clin Pharmacol. 2020; ; 86 (6): 1178-1179.
Kulemina LV, Ostrov DA. Prediction of off-target effects on angiotensin-converting enzyme 2. J Biomol Screen. 2011; 16: 878-885.
Benedetti CWM, Zaza G, Riella LV, Cravedi P. COVID-19 and the kidneys: an update. Front Med. 020-06-30. | https://doi.org/10.3389/fmed.2020.00423.
Rizk JG, Kalantar-Zadeh K, Mehra MR, Lavie CJ, Rizk Y, Forthal DN. Pharmaco-immunomodulatory therapy in COVID-19. Drugs. 2020.
https://http://www.covid19-druginteractions.org/ Last Update:9/04/2020.